(1S,9R,10R,11S,14S,15S)-15-methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl](13,13,14-2H3)tetracyclo[8.7.0.02,7.011,15]heptadeca-2,4,6-triene-5,14-diol

• ChemBase编号: 169491
• 分子式: C32H47F5O3S
• 平均质量: 606.770796
• 单一同位素质量: 606.31660746
• SMILES: c1c(cc2c(c1)[C@@H]1[C@@H]([C@@H](C2)CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]2[C@](CC1)([C@H](CC2)O)C)O
• Canonical SMILES: O=S(CCCC(C(F)(F)F)(F)F)CCCCCCCCC[C@@H]1Cc2cc(O)ccc2[C@@H]2[C@@H]1[C@@H]1CC[C@@H]([C@]1(CC2)C)O
• InChI: InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChIKey: VWUXBMIQPBEWFH-WCCTWKNTSA-N

名称和登记号

名称

• IUPAC标准名: (1S,9R,10R,11S,14S,15S)-15-methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl](13,13,14-^2H₃)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadeca-2,4,6-triene-5,14-diol
• IUPAC传统名: (1S,9R,10R,11S,14S,15S)-15-methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl](13,13,14-^2H₃)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadeca-2,4,6-triene-5,14-diol
• 别名: (7α,17β)-7-[9-[4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol-d3; Faslodex-d3; Fulvestrant-d3; ICI 182780-d3; ZD 182780-d3; ZD 9238-d3; ZM 182780-d3; Fulvestrant-d3

登记号

• PubChem SID: 162263623
• PubChem CID: 46781670

理论计算性质

• Acid pKa: 10.320843
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 7.571834
• LogD (pH = 7.4): 7.571323
• Log P: 7.571841
• 摩尔折射率: 155.337 cm^3
• 极化性: 59.35865 Å^3
• 极化表面积: 57.53 Å^2
• 可自由旋转的化学键: 15
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Methanol
• 外观: White Solid
• 熔点: 128-130°C

安全信息

• 保存条件: -20°C Freezer

详细说明

Toronto Research Chemicals - F862502

A novel labelled steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).

参考文献

• Wakeling, A.E., et al.: Cancer Res., 51, 3867 (1991)
• Howell, A., et al.: Br. J. Cancer, 74, 300 (1991)
• Robertson, J.F., et al.: Cancer Res., 61, 6739 (1991)